Navigation Links
Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
Date:10/23/2011

iRNAs, as Silence has clearly been shown to be at the forefront of efficient and safe delivery of siRNAs and miRNAs, a process critical to the ultimate success of what promises to be a new and exciting class of targeted cancer therapeutics. Mirna has developed a strong intellectual property position in the therapeutic use of miRNAs in cancer, and has established a broad pipeline of key tumor suppressor miRNAs as potential new targeted therapeutic candidates against both solid and haematological cancers. An efficient delivery technology that provides for systemic delivery of therapeutically effective dose-levels of these miRNAs to their intended targets is a key element in their potential success in the clinic."

Silence's proprietary lipid delivery technology AtuPLEX™ has demonstrated the broad systemic delivery to the vascular endothelium. Formulations generated with the AtuPLEX™ technology can be lyophilized (freeze dried) significantly improving stability, shipping and handling.

Silence is currently conducting a Phase I trial with Atu027 which is based on AtuPLEX™ in patients with advanced solid cancer. Interim data analysis from this trial were presented at the 2011 American Society of Clinical Oncology conference and showed that Atu027 is safe and well tolerated and provided broad support for AtuPLEX™ as an effective siRNA delivery technology with the potential to overcome the recognized delivery challenges currently associated with RNAi therapeutics.

DBTC is the latest delivery system developed by scientists at Silence and allows functional targeted delivery to the liver. Unlike Silence's established delivery technologies, DBTC is a novel lipid-based formulation that functionally delivers to liver endothelial cells, hepatocytes and to other cell types of the liver. As with AtuPLEX™, DBTC can be lyophilized.

Notes for editors                 <
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
2. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
3. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
4. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
7. Silence Therapeutics Appoints New Vice President of Research
8. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
9. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
10. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
11. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Clinverse, ... company for clinical trials, announced today it has ... LLC. Clinverse’s ClinPay® FLS eClinical commerce platform ... process. SpendMD ™, Aggregate Spend Solutions’ ... for tracking and reporting transfer of value at ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)...  Personal Genome Diagnostics Inc. (PGDx), today announced ... expertise in genomic analysis of defined cancer subtypes ... Blueprint Medicines.  PGDx is an innovator in conducting ... tumors, and Blueprint Medicines is an expert in ... defined patient population. "This collaboration brings ...
(Date:5/21/2013)... Inflamax scientists worked closely with ... design the study, which will provide critical insight ... used in the study of allergy treatments, the ... (NAC) models. Although both the models are well ... no direct comparison between the allergic responses evoked ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... have succeeded in changing the genetic material of cancer ... in nanosurgery opens the door to new medical applications, ... A light scalpel to treat cancerous cells, The ... team uses a femtosecond laser (a laser with ultra-short ...
... GeneLink Biosciences, Inc. (OTCBB: GNLK), a leading consumer ... the stock of its wholly owned direct-selling subsidiary ... (OTCBB: WELL), another public company operating in the ... and Capsalus executed definitive agreements for the sale ...
... 2012 Senior analysts from The Advisory Board Company,s ... Vegas preparing to provide an immediate analysis of the ... Management Systems Society,s HIMSS12 Annual Conference and Exhibition, which ... http://photos.prnewswire.com/prnh/20110802/PH45999LOGO ) By Monday, the ...
Cached Biology Technology:GeneLink Biosciences Completes Sale of GeneWize Life Sciences 2Meaningful Use Stage Two: The Advisory Board Company Helps Hospitals Set Strategy 2Meaningful Use Stage Two: The Advisory Board Company Helps Hospitals Set Strategy 3
(Date:5/18/2013)... presented today at Digestive Disease Week (DDW) explores new ... impact of coffee on autoimmune disease and palliative care ... has been associated with reduced risk of fibrosis, a ... of java each month also correlate with lower risk ... Mayo Clinic, Rochester, MN, linked coffee consumption with reduced ...
(Date:5/18/2013)... (May 18, 2013) An increasing number of ... interventions to resolve, according to research presented at ... study targeting obesity, researchers at the Cleveland Clinic ... unique pattern of exhaled breath compared to their ... organic compound levels that can be correlated to ...
(Date:5/17/2013)... the white noise of the South, but the night belongs ... air hangs heavy from the humidity and the sounds of ... species of frogs, toads and salamanders, is the center of ... swamps are the auditorium for their symphonic choruses, the scientists ... or ARMI, have front-row seats. , Amphibians, which ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... different gene mutations, but just how these mutations contribute to ... new clue comes from scientists at the University of North ... Their research indicates that early life sun exposure, from birth ... melanomas with BRAF gene mutations. A different mutation, on the ...
... were estimated to be living with Alzheimer’s disease in 2006, ... Hopkins Bloomberg School of Public Health. The researchers also concluded ... than 106 million by 2050. By that time, 43 percent ... to that of a nursing home. The findings were presented ...
... at x-rays of hands, searching out the telltale signs of ... arthritis. With these clinical features at his side, he turns ... genome – to figure out what makes these people susceptible ... finally closed the circle between key genes identified in his ...
Cached Biology News:Sun exposure early in life linked to specific skin cancer gene mutation 2Alzheimer's disease to quadruple worldwide by 2050 2Breakthrough developments in rheumatoid arthritis reported 2Breakthrough developments in rheumatoid arthritis reported 3Breakthrough developments in rheumatoid arthritis reported 4
Form: Ready to use Applications: ELISA...
Request Info...
Form: Concentrated Applications: ELISA...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
Biology Products: